Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation

Area of Science:

• Hematology
• Oncology
• Stem Cell Transplantation

Background:

• FMS-like tyrosine kinase 3 (FLT3) mutations are common in acute myeloid leukemia (AML).
• The role of minimal residual disease (MRD) detected by PCR before allogeneic stem cell transplantation (SCT) in FLT3-mutated AML is not fully understood.
• Predicting outcomes after SCT in FLT3-AML patients requires further investigation into pre-transplant prognostic factors.

Purpose of the Study:

• To evaluate the significance of pre-transplant MRD status by PCR in patients with FLT3-mutated AML undergoing SCT.
• To identify key predictors of relapse and survival in this patient population.
• To clarify the impact of MRD on outcomes following allogeneic SCT for FLT3-AML.

Main Methods:

• Retrospective analysis of 200 patients with FLT3-mutated AML who underwent SCT.
• Categorization of patients based on disease status at transplant: complete remission (CR1/CR2), high-risk CR (CR-HR), and active disease (AD).
• Assessment of MRD by PCR prior to SCT and correlation with relapse rates, overall survival, and progression-free survival.

Main Results:

• Relapse rates varied significantly based on disease status and MRD positivity, ranging from 23% in CR1/CR2 MRD-negative to 85% in AD.
• Detectable morphological disease and FLT3 MRD by PCR pre-transplant were independent predictors of relapse on multivariate analysis.
• Age, graft type, graft source, FLT3 mutation type, and conditioning intensity did not significantly influence relapse risk.

Conclusions:

• Morphologic and molecular remission status before SCT are critical predictors of relapse and survival in FLT3-AML patients.
• Pre-transplant MRD detection by PCR is a valuable tool for risk stratification and outcome prediction in FLT3-AML undergoing SCT.
• Optimizing pre-transplant disease control is essential for improving outcomes in FLT3-mutated AML.